Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412932 · ClinicalTrials.gov registry record · Phase 4
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
A Phase 4 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 178
- Enrollment target
NCT00412932 is a Phase 4 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 178 participants.
The verdict
NCT00412932, a Phase 4 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 178 participants
- Enrollment target
Study Summary
This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
Interventions
- DRUG Olmesartan medoxomil
- DRUG Olmesartan medoxomil/hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412932
The ClinicalTrials.gov registry entry for NCT00412932 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olmesartan medoxomil is the first listed.
NCT00412932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412932 about?
NCT00412932 is a clinical study titled "An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension". This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure. The medication being tested has been approved by the FDA for the treatment of high blood pressure.
What is the current status of trial NCT00412932?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 178 participants. The study started on 2006-12. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00412932?
The interventions under investigation include: Olmesartan medoxomil (DRUG), Olmesartan medoxomil/hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00412932?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.